Veraxa Biotech AG (VRXA) Balance Sheet

NASDAQ: VRXAAssets, liabilities, debt and equity over 3 years.

VRXA balance sheet, 2025

December 31, 2025 · Swiss francs

CHF 80.8M assets = CHF 96.6M liabilities + −CHF 15.8M equity

What it ownsCHF 80.8MCash & ST investments: CHF 1.6M (2.0%)Other current: CHF 1.3M (1.6%)PP&E: CHF 3.1M (3.8%)Goodwill & intangibles: CHF 74.8M (92.5%)Goodwill & intangiblesCHF 74.8M · 92%Other non-current: CHF 70,718 (0.1%)=How it is financedCHF 96.6MCurrent liabilities: CHF 6.6M (6.8%)CHF 6.6MOther LT liabilities: CHF 90.0M (93.2%)Other LT liabilitiesCHF 90.0M · 93%

Liabilities exceed assets: shareholders’ equity is negative (−CHF 15.8M).

Both columns are drawn to the same scale: what VRXA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

VRXA financial health

Current ratio0.44
Tight · current assets cover current liabilities 0.44×
Equity / assets−19.5%
Thin equity · of assets funded by shareholders
Goodwill & intangibles92.5%
Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

VRXA balance sheet trends, 2023–2025

MetricTrendThenLatestChange
Total assetsCHF 91.9M2023CHF 80.8M2025−6.2%/yr
Total liabilitiesCHF 36.8M2023CHF 96.6M2025+62.0%/yr
Shareholders’ equityCHF 55.1M2023−CHF 15.8M2025—
Cash & short-term investmentsCHF 11.4M2023CHF 1.6M2025−62.3%/yr
Working capitalCHF 10.3M2023−CHF 3.7M2025CHF 14.0M
Current ratio7.3920230.442025−6.95
Shares outstanding141.4M2023141.4M20250.0%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

VRXA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

VRXA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

VRXA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

VRXA balance sheet in Swiss francs

202520242023
Assets
Cash & short-term investmentsCHF 1.6MCHF 5.4MCHF 11.4M
Cash & equivalentsCHF 1.6MCHF 5.4MCHF 11.4M
ReceivablesCHF 0CHF 0CHF 0
InventoryCHF 0CHF 0CHF 0
Other current assetsCHF 1.3MCHF 243,688CHF 526,034
Total current assetsCHF 2.9MCHF 5.6MCHF 11.9M
Property, plant & equipment (net)CHF 3.1MCHF 2.8MCHF 2.1M
Goodwill & intangible assetsCHF 74.8MCHF 76.3MCHF 77.9M
Long-term investmentsCHF 0CHF 0CHF 0
Other non-current assetsCHF 70,718CHF 0CHF 0
Total assetsCHF 80.8MCHF 84.8MCHF 91.9M
Liabilities
Accounts payableCHF 1.4MCHF 488,543CHF 611,575
Total current liabilitiesCHF 6.6MCHF 2.5MCHF 1.6M
Long-term debtCHF 0CHF 0CHF 0
Lease obligationsCHF 1.1MCHF 864,485CHF 0
Other long-term liabilitiesCHF 90.0MCHF 51.2MCHF 35.2M
Total liabilitiesCHF 96.6MCHF 53.7MCHF 36.8M
Shareholders' equity
Retained earnings (deficit)−CHF 98.5M−CHF 31.9M−CHF 3.7M
Total shareholders' equity−CHF 15.8MCHF 31.1MCHF 55.1M
Key figures
Working capital−CHF 3.7MCHF 3.1MCHF 10.3M
Tangible book value−CHF 90.5M−CHF 45.3M−CHF 22.8M
Shares outstanding141.4M141.4M141.4M
Current ratio0.442.207.39
Quick ratio0.242.117.06
Equity / assets−19.5%36.6%60.0%

Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported (latest annual report filed —); data from EODHD.

VRXA financial position

At the end of fiscal 2025 (December 31, 2025), Veraxa Biotech had total assets of CHF 80.8 million (down 4.7% from a year earlier), total liabilities of CHF 96.6 million and shareholders' equity of -CHF 15.8 million. Its current ratio was 0.44.

Related: VRXA income statement, VRXA cash flow statement, VRXA key metrics. See the VRXA stock overview for the latest quote and news.

VRXA balance sheet FAQ

What are Veraxa Biotech's total assets?

Veraxa Biotech reported total assets of CHF 80.8 million at the end of fiscal 2025 (December 31, 2025), compared with CHF 84.8 million a year earlier.

How much cash does Veraxa Biotech have?

Veraxa Biotech held CHF 1.6 million in cash and short-term investments at the end of fiscal 2025.

What is Veraxa Biotech's book value?

Veraxa Biotech's shareholders' equity (book value) was -CHF 15.8 million at the end of fiscal 2025.

What is Veraxa Biotech's current ratio?

Veraxa Biotech had current assets of CHF 2.9 million and current liabilities of CHF 6.6 million, a current ratio of 0.44 (current liabilities exceed current assets).

How much goodwill does Veraxa Biotech have?

Veraxa Biotech carried CHF 74.8 million of goodwill and intangible assets, 92.5% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet